Track the compliance plan submission deadline (Oct 15, 2026) and any Nasdaq decision on extension. The proposed delisting risk may accelerate share price decline; failure to regain compliance could lead to a halt in trading and loss of institutional ownership.
Price Chart
Executive Summary
Quince Therapeutics received a Nasdaq delisting notice on August 31, 2026, for failing the minimum stockholders' equity requirement ($10M) with reported equity of -$35.32M as of June 30, 2026. The company has until October 15, 2026, to submit a compliance plan or face potential delisting from the Nasdaq Global Select Market. A proposed name change to IRulya Therapeutics Inc. and transfer to the Nasdaq Capital Market under IRLA is pending stockholder approval, but the severe negative equity and recent dilutive S-3 filing heighten the risk of delisting.
Key Facts
- Stockholders' equity as of June 30, 2026 was ($35,324,000), far below the $10M Nasdaq minimum
- Company received delisting notice on Aug 31, 2026 for non-compliance with Nasdaq Listing Rule 5450(b)(1)(A)
- Must submit a compliance plan by October 15, 2026 (45 calendar days)
- If plan accepted, Nasdaq may grant an extension up to February 27, 2027 (180 days from notice)
- Company is pursuing a name change to IRulya Therapeutics Inc. and Nasdaq Capital Market listing under IRLA
- An S-3/A shelf registration for up to 15,470,099 shares was filed 30 days prior, indicating recent capital needs
Financial Impact
Negative stockholders' equity of $35.32M and need to raise at least $10M to regain compliance; market cap is $33M, so compliance could require significant dilutive financing
Risk Factors
- High probability of delisting if equity cannot be restored within the compliance period
- Potential for further dilutive capital raise to meet the $10M equity minimum
- Loss of Nasdaq listing would severely reduce liquidity and institutional investor access
- Name change and transfer to Nasdaq Capital Market is contingent on stockholder and Nasdaq approval—no guarantee
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-382838 |
| Document: 0001193125-26-382838-index-headers.html | 0001193125-26-382838 |
| Document: 0001193125-26-382838-index.html | 0001193125-26-382838 |
| Document: 0001193125-26-382838.txt | 0001193125-26-382838 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | 8-K | $31.32 $28.59 | ▲ +8.72% | ▲ +7.51% | $30.67 (+2.08%) |
Aug 25, 2026 5w ago | EFFECT | $30.93 $32.11 | ▼ −3.82% | ▼ −4.35% | $30.67 (+0.84%) |
Aug 14, 2026 7w ago | 8-K | $31.34 awaiting T+5 | awaiting T+5 | — | $30.67 (−2.14%) |
Aug 14, 2026 7w ago | Press Release | $31.34 awaiting T+5 | awaiting T+5 | — | $30.67 (−2.14%) |
Aug 5, 2026 8w ago | S-3/A | $28.88 $31.26 | ▲ +8.24% | ▲ +7.89% | $30.67 (+6.20%) |
Jun 11, 2026 16w ago | 3 | $0.9337 $0.9451 | ▲ +1.22% | ▲ +0.55% | $30.67 (+3184.78%) |
May 18, 2026 19w ago | 8-K | $19.90 $24.00 | ▲ +20.60% | ▲ +18.99% | $30.67 (+54.12%) |
Apr 27, 2026 22w ago | DEFA14A | $24.60 $24.60 | · 0.00% | ▼ −1.70% | $30.67 (+24.67%) |
Apr 9, 2026 25w ago | 8-K | $1.24 $1.34 | ▲ +8.06% | ▲ +4.88% | $30.67 (+2373.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access